Barclays
DAWN

Barclays’s Day One Biopharmaceuticals DAWN Stock Holding History

Barclays’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$647K Sell
30,163
-262,162
-90% -$3.69M ﹤0.01% 3032
2025
Q4 		$2.72M Sell
292,325
-54,860
-16% -$458K ﹤0.01% 2704
2025
Q3 		$2.45M Sell
347,185
-924
-0.3% -$6.36K ﹤0.01% 2739
2025
Q2 		$2.26M Buy
348,109
+192,900
+124% +$1.33M ﹤0.01% 2750
2025
Q1 		$1.23M Buy
155,209
+13,757
+10% +$148K ﹤0.01% 2975
2024
Q4 		$1.79M Buy
141,452
+6,079
+4% +$84.6K ﹤0.01% 2968
2024
Q3 		$1.89M Buy
135,373
+79,779
+144% +$1.14M ﹤0.01% 2900
2024
Q2 		$766K Sell
55,594
-11,872
-18% -$174K ﹤0.01% 2762
2024
Q1 		$1.11M Sell
67,466
-118,373
-64% -$1.77M ﹤0.01% 3032
2023
Q4 		$2.71M Buy
185,839
+53,957
+41% +$654K ﹤0.01% 2660
2023
Q3 		$1.62M Sell
131,882
-12,521
-9% -$163K ﹤0.01% 2015
2023
Q2 		$1.72M Buy
144,403
+70,834
+96% +$925K ﹤0.01% 1973
2023
Q1 		$984K Sell
73,569
-35,983
-33% -$703K ﹤0.01% 2744
2022
Q4 		$2.36M Buy
109,552
+19,123
+21% +$392K ﹤0.01% 2153
2022
Q3 		$1.81M Buy
90,429
+89,257
+7,616% +$1.9M ﹤0.01% 1821
2022
Q2 		$21K Sell
1,172
-4,315
-79% -$44.6K ﹤0.01% 4373
2022
Q1 		$55K Buy
+5,487
New +$72.5K ﹤0.01% 4079

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Barclays's DAWN Position: Q1 2026 in Review

Barclays reduced its Day One Biopharmaceuticals (DAWN) stake by 90% in Q1 2026, selling an estimated $3.69M and leaving 30,163 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #3032.

Barclays first reported a position in DAWN in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.72M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Barclays held 30,163 shares of Day One Biopharmaceuticals worth $647K as of Q1 2026.
  • Barclays sold 262,162 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3.69M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3032 holding.
  • Barclays first reported a position in Day One Biopharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Day One Biopharmaceuticals position peaked at $2.72M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.